{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:13:57Z","timestamp":1788754437375,"version":"build-2803163510"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sohag University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In November 2021, variant B.1.1.529 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified by the World Health Organization (WHO) and designated Omicron. Omicron is characterized by a high number of mutations, thirty-two in total, making it more transmissible than the original virus. More than half of those mutations were found in the receptor-binding domain (RBD) that directly interacts with human angiotensin-converting enzyme 2 (ACE2). This study aimed to discover potent drugs against Omicron, which were previously repurposed for coronavirus disease 2019 (COVID-19). All repurposed anti-COVID-19 drugs were compiled from previous studies and tested against the RBD of SARS-CoV-2 Omicron.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>As a preliminary step, a molecular docking study was performed to investigate the potency of seventy-one compounds from four classes of inhibitors. The molecular characteristics of the best-performing five compounds were predicted by estimating the drug-likeness and drug score. Molecular dynamics simulations (MD) over 100\u00a0ns were performed to inspect the relative stability of the best compound within the Omicron receptor-binding site.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The current findings point out the crucial roles of Q493R, G496S, Q498R, N501Y, and Y505H in the RBD region of SARS-CoV-2 Omicron. Raltegravir, hesperidin, pyronaridine, and difloxacin achieved the highest drug scores compared with the other compounds in the four classes, with values of 81%, 57%, 18%, and 71%, respectively. The calculated results showed that raltegravir and hesperidin had high binding affinities and stabilities to Omicron with \u0394<jats:italic>G<\/jats:italic><jats:sub>binding<\/jats:sub> of\u2009\u2212\u200975.7304\u2009\u00b1\u20090.98324 and\u2009\u2212\u200942.693536\u2009\u00b1\u20090.979056\u00a0kJ\/mol, respectively. Further clinical studies should be performed for the two best compounds from this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00894-023-05457-z","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T17:14:40Z","timestamp":1677172480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-0725","authenticated-orcid":false,"given":"Eslam A. R.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam M.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi E. A.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al-Khdhairawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad M.","family":"Alqaisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyana binti Abd","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Abu-Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza A. K.","family":"El-Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed F.","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-5831","authenticated-orcid":false,"given":"Heba Ali","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"10224","key":"5457_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224):565\u2013574. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8","journal-title":"Lancet"},{"issue":"7798","key":"5457_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265\u2013269. https:\/\/doi.org\/10.1038\/s41586-020-2008-3","journal-title":"Nature"},{"issue":"2","key":"5457_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/joim.13091","volume":"288","author":"G Pascarella","year":"2020","unstructured":"Pascarella G et al (2020) COVID-19 diagnosis and management: a comprehensive review. J Intern Med 288(2):192\u2013206. https:\/\/doi.org\/10.1111\/joim.13091","journal-title":"J Intern Med"},{"issue":"5","key":"5457_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li Q et al (2020) The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182(5):1284-1294.e9. https:\/\/doi.org\/10.1016\/j.cell.2020.07.012","journal-title":"Cell"},{"issue":"7","key":"5457_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey WT et al (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19(7):409\u2013424. https:\/\/doi.org\/10.1038\/s41579-021-00573-0","journal-title":"Nat Rev Microbiol"},{"key":"5457_CR6","doi-asserted-by":"publisher","unstructured":"Doria-Rose NA et al (2021) \u201cBooster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization,\u201d medRxiv, p. 2021.12.15.21267805. https:\/\/doi.org\/10.1101\/2021.12.15.21267805","DOI":"10.1101\/2021.12.15.21267805"},{"key":"5457_CR7","doi-asserted-by":"publisher","unstructured":"Mahase C (2021) COVID-19: do vaccines work against omicron{\\textemdash}and other questions answered.\u00a0BMJ 375. https:\/\/doi.org\/10.1136\/bmj.n3062","DOI":"10.1136\/bmj.n3062"},{"issue":"4","key":"5457_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko M, Marzi A, Munster V (2020) Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5(4):562\u2013569. https:\/\/doi.org\/10.1038\/s41564-020-0688-y","journal-title":"Nat Microbiol"},{"issue":"8","key":"5457_CR9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1473-3099(21)00262-0","volume":"21","author":"M Ramanathan","year":"2021","unstructured":"Ramanathan M, Ferguson ID, Miao W, Khavari PA (2021) \u201cSARS-CoV-2 B.1.1.7 and B.1.3.5.1 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis 21(8):1070. https:\/\/doi.org\/10.1016\/S1473-3099(21)00262-0","journal-title":"Lancet Infect Dis"},{"issue":"7838","key":"5457_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","volume":"588","author":"Z Ke","year":"2020","unstructured":"Ke Z et al (2020) Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588(7838):498\u2013502. https:\/\/doi.org\/10.1038\/s41586-020-2665-2","journal-title":"Nature"},{"issue":"1","key":"5457_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11357-021-00500-4","volume":"44","author":"J Quarleri","year":"2022","unstructured":"Quarleri J, Galvan V, Delpino MV (2022) Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load. GeroScience 44(1):53\u201356. https:\/\/doi.org\/10.1007\/s11357-021-00500-4","journal-title":"GeroScience"},{"issue":"4","key":"5457_CR12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/bib\/bbw051","volume":"18","author":"F Cheng","year":"2017","unstructured":"Cheng F, Hong H, Yang S, Wei Y (2017) Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. Brief Bioinform 18(4):682\u2013697. https:\/\/doi.org\/10.1093\/bib\/bbw051","journal-title":"Brief Bioinform"},{"issue":"1","key":"5457_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov 6(1):14. https:\/\/doi.org\/10.1038\/s41421-020-0153-3","journal-title":"Cell Discov"},{"key":"5457_CR14","doi-asserted-by":"publisher","unstructured":"Shionoya et al (2021) Mefloquine, a potent anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) drug as an entry inhibitor in vitro.\u00a0Front Microbiol 12. 2021, [Online]. Available: https:\/\/www.frontiersin.org\/article\/https:\/\/doi.org\/10.3389\/fmicb.2021.651403","DOI":"10.3389\/fmicb.2021.651403"},{"issue":"5","key":"5457_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.joim.2021.07.003","volume":"19","author":"AD Fuzimoto","year":"2021","unstructured":"Fuzimoto AD (2021) An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment. J Integr Med 19(5):375\u2013388. https:\/\/doi.org\/10.1016\/j.joim.2021.07.003","journal-title":"J Integr Med"},{"issue":"4","key":"5457_CR16","doi-asserted-by":"publisher","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","volume":"55","author":"P Colson","year":"2020","unstructured":"Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 55(4):105932. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105932","journal-title":"Int J Antimicrob Agents"},{"issue":"Supplement_1","key":"5457_CR17","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/ofid\/ofab466.724","volume":"8","author":"MK Jain","year":"2021","unstructured":"Jain MK et al (2021) 525 Atovaquone for treatment of COVID-19 (Ataq COVID-19) trial. Open Forum Infect Dis 8(Supplement_1):S363\u2013S364. https:\/\/doi.org\/10.1093\/ofid\/ofab466.724","journal-title":"Open Forum Infect Dis"},{"key":"5457_CR18","doi-asserted-by":"publisher","unstructured":"Jain MK et al (2022) Atovaquone for treatment of COVID-19: a prospective randomized, double-blind, placebo-controlled clinical trial.\u00a0Front Pharmacol 13.\u00a0https:\/\/doi.org\/10.3389\/fphar.2022.1020123","DOI":"10.3389\/fphar.2022.1020123"},{"issue":"6","key":"5457_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1021\/acsinfecdis.2c00091","volume":"8","author":"AC Puhl","year":"2022","unstructured":"Puhl AC et al (2022) Pyronaridine protects against SARS-CoV-2 infection in mouse. ACS Infect Dis 8(6):1147\u20131160. https:\/\/doi.org\/10.1021\/acsinfecdis.2c00091","journal-title":"ACS Infect Dis"},{"key":"5457_CR20","doi-asserted-by":"publisher","unstructured":"EBioMedicine (2021) COVID-19 and malaria, a tale of two diseases.\u00a0EBioMedicine 70:103554. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103554","DOI":"10.1016\/j.ebiom.2021.103554"},{"issue":"10","key":"5457_CR21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1089\/omi.2020.0071","volume":"24","author":"C Sachdeva","year":"2020","unstructured":"Sachdeva C, Wadhwa A, Kumari A, Hussain F, Jha P, Kaushik NK (2020) In silico potential of approved antimalarial drugs for repurposing against COVID-19. Omi A J Integr Biol 24(10):568\u2013580. https:\/\/doi.org\/10.1089\/omi.2020.0071","journal-title":"Omi A J Integr Biol"},{"issue":"9","key":"5457_CR22","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1021\/acsinfecdis.0c00522","volume":"6","author":"R Cao","year":"2020","unstructured":"Cao R et al (2020) Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect Dis 6(9):2524\u20132531. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00522","journal-title":"ACS Infect Dis"},{"key":"5457_CR23","doi-asserted-by":"publisher","unstructured":"Hu Y et al (2021) Artemether, artesunate, arteannuin B, echinatin, licochalcone B and andrographolide effectively inhibit SARS-CoV-2 and related viruses in vitro. Front Cell Infect Microbiol 11. https:\/\/doi.org\/10.3389\/fcimb.2021.680127.","DOI":"10.3389\/fcimb.2021.680127"},{"key":"5457_CR24","doi-asserted-by":"publisher","first-page":"101873","DOI":"10.1016\/j.tmaid.2020.101873","volume":"37","author":"M Gendrot","year":"2020","unstructured":"Gendrot M et al (2020) Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation. Travel Med Infect Dis 37:101873. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101873","journal-title":"Travel Med Infect Dis"},{"issue":"6","key":"5457_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/v12060642","volume":"12","author":"A Ianevski","year":"2020","unstructured":"Ianevski A et al (2020) Potential antiviral options against SARS-CoV-2 infection. Viruses 12(6):642. https:\/\/doi.org\/10.3390\/v12060642","journal-title":"Viruses"},{"issue":"4","key":"5457_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/v13040647","volume":"13","author":"M Gro\u00dfe","year":"2021","unstructured":"Gro\u00dfe M et al (2021) Quinine inhibits infection of human cell lines with SARS-CoV-2. Viruses 13(4):647. https:\/\/doi.org\/10.3390\/v13040647","journal-title":"Viruses"},{"key":"5457_CR27","doi-asserted-by":"publisher","unstructured":"(2020) Dexamethasone in hospitalized patients with COVID-19.\u00a0N Engl J Med 384(8):693\u2013704.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2021436","DOI":"10.1056\/NEJMoa2021436"},{"key":"5457_CR28","doi-asserted-by":"publisher","first-page":"173854","DOI":"10.1016\/j.ejphar.2021.173854","volume":"894","author":"S Noreen","year":"2021","unstructured":"Noreen S, Maqbool I, Madni A (2021) Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol 894:173854. https:\/\/doi.org\/10.1016\/j.ejphar.2021.173854","journal-title":"Eur J Pharmacol"},{"key":"5457_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/nu13082800","volume":"13","author":"F-J Cheng","year":"2021","unstructured":"Cheng F-J et al (2021) \u201cHesperidin is a potential inhibitor against SARS-CoV-2 infection. Nutrients 13:8. https:\/\/doi.org\/10.3390\/nu13082800","journal-title":"Nutrients"},{"key":"5457_CR30","unstructured":"NCT04452799, \u201cHesperidin and diosmin for treatment of COVID-19,\u201d\nhttps:\/\/clinicaltrials.gov\/show\/NCT04452799, 2020, [Online]. Available:\nhttps:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02134028\/full"},{"issue":"7","key":"5457_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.reuma.2020.05.001","volume":"17","author":"G Montealegre-G\u00f3mez","year":"2021","unstructured":"Montealegre-G\u00f3mez G, Garavito E, G\u00f3mez-L\u00f3pez A, Rojas-Villarraga A, Parra-Medina R (2021) Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatol Cl\u00ednica 17(7):371\u2013375. https:\/\/doi.org\/10.1016\/j.reuma.2020.05.001","journal-title":"Reumatol Cl\u00ednica"},{"issue":"5","key":"5457_CR32","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1021\/acscentsci.0c01186","volume":"7","author":"HS Lo","year":"2021","unstructured":"Lo HS et al (2021) Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir. ACS Cent Sci 7(5):792\u2013802. https:\/\/doi.org\/10.1021\/acscentsci.0c01186","journal-title":"ACS Cent Sci"},{"issue":"1","key":"5457_CR33","doi-asserted-by":"publisher","first-page":"106499","DOI":"10.1016\/j.ijantimicag.2021.106499","volume":"59","author":"E Muturi","year":"2022","unstructured":"Muturi E et al (2022) Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice. Int J Antimicrob Agents 59(1):106499. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106499","journal-title":"Int J Antimicrob Agents"},{"key":"5457_CR34","doi-asserted-by":"publisher","unstructured":"Salari S, Karbasforooshan H, Hosseinjani H (2022) Anti-HIV integrase inhibitors as new candidates for the treatment of COVID-19: a narrative literature review.\u00a0\u00a0Anti-Infec Agents 20(2).\u00a0https:\/\/doi.org\/10.2174\/2211352519666210928110627","DOI":"10.2174\/2211352519666210928110627"},{"key":"5457_CR35","doi-asserted-by":"publisher","unstructured":"Stoeckle K et al (2020)\u00a0 COVID-19 in hospitalized adults with HIV .Open Forum Infect Dis 7(8).\u00a0https:\/\/doi.org\/10.1093\/ofid\/ofaa327","DOI":"10.1093\/ofid\/ofaa327"},{"issue":"10334","key":"5457_CR36","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/S0140-6736(22)00280-X","volume":"399","author":"L Waters","year":"2022","unstructured":"Waters L, Marra F, Pozniak A, Cockburn J, Boffito M (2022) Ritonavir and COVID-19: pragmatic guidance is important. Lancet 399(10334):1464\u20131465. https:\/\/doi.org\/10.1016\/S0140-6736(22)00280-X","journal-title":"Lancet"},{"issue":"7","key":"5457_CR37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/biom12070944","volume":"12","author":"M Pereira","year":"2022","unstructured":"Pereira M, Vale N (2022) Saquinavir: from HIV to COVID-19 and cancer treatment. Biomolecules 12(7):944. https:\/\/doi.org\/10.3390\/biom12070944","journal-title":"Biomolecules"},{"issue":"12","key":"5457_CR38","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00894-020-04600-4","volume":"26","author":"M Bello","year":"2020","unstructured":"Bello M, Mart\u00ednez-Mu\u00f1oz A, Balbuena-Rebolledo I (2020) Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM\/GBSA. J Mol Model 26(12):340. https:\/\/doi.org\/10.1007\/s00894-020-04600-4","journal-title":"J Mol Model"},{"issue":"10259","key":"5457_CR39","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","volume":"396","author":"PW Horby","year":"2020","unstructured":"Horby PW et al (2020) Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 396(10259):1345\u20131352. https:\/\/doi.org\/10.1016\/S0140-6736(20)32013-4","journal-title":"Lancet"},{"issue":"12","key":"5457_CR40","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.jiph.2020.10.015","volume":"13","author":"P Indu","year":"2020","unstructured":"Indu P, Rameshkumar MR, Arunagirinathan N, Al-Dhabi NA, ValanArasu M, Ignacimuthu S (2020) Raltegravir, indinavir, tipranavir, dolutegravir, and etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: a molecular docking and drug repurposing approach. J. Infect. Public Health 13(12):1856\u20131861. https:\/\/doi.org\/10.1016\/j.jiph.2020.10.015","journal-title":"J. Infect. Public Health"},{"key":"5457_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.12.246389","author":"KH Risner","year":"2020","unstructured":"Risner KH et al (2020) Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture. BioRxiv the preprint server for biology. https:\/\/doi.org\/10.1101\/2020.08.12.246389","journal-title":"BioRxiv the preprint server for biology"},{"issue":"6","key":"5457_CR42","doi-asserted-by":"publisher","first-page":"BSR20201256","DOI":"10.1042\/BSR20201256","volume":"40","author":"A Shamsi","year":"2020","unstructured":"Shamsi A et al (2020) Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. Biosci Rep. 40(6):BSR20201256. https:\/\/doi.org\/10.1042\/BSR20201256","journal-title":"Biosci Rep."},{"issue":"3","key":"5457_CR43","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jac\/dkaa501","volume":"76","author":"F Roozbeh","year":"2021","unstructured":"Roozbeh F et al (2021) Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother 76(3):753\u2013757. https:\/\/doi.org\/10.1093\/jac\/dkaa501","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"5457_CR44","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1002\/jmv.27264","volume":"93","author":"S Abbass","year":"2021","unstructured":"Abbass S et al (2021) Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: a randomized controlled trial. J Med Virol 93(12):6750\u20136759. https:\/\/doi.org\/10.1002\/jmv.27264","journal-title":"J Med Virol"},{"issue":"4","key":"5457_CR45","doi-asserted-by":"publisher","first-page":"102367","DOI":"10.1016\/j.isci.2021.102367","volume":"24","author":"H Ohashi","year":"2021","unstructured":"Ohashi H et al (2021) Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 24(4):102367. https:\/\/doi.org\/10.1016\/j.isci.2021.102367","journal-title":"iScience"},{"issue":"1","key":"5457_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40709-021-00149-2","volume":"28","author":"UC Halder","year":"2021","unstructured":"Halder UC (2021) Predicted antiviral drugs darunavir, amprenavir, rimantadine and saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins. J Biol Res (Thessalonike, Greece) 28(1):18. https:\/\/doi.org\/10.1186\/s40709-021-00149-2","journal-title":"J Biol Res (Thessalonike, Greece)"},{"key":"5457_CR47","doi-asserted-by":"publisher","unstructured":"Di Castelnuovo A et al (2021) \u201cLopinavir\/ritonavir and darunavir\/cobicistat in hospitalized COVID-19 patients: findings from the multicenter Italian CORIST study ,\u201d Frontiers in Medicine , vol. 8. 2021, [Online]. Available: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fmed.2021.639970","DOI":"10.3389\/fmed.2021.639970"},{"key":"5457_CR48","doi-asserted-by":"publisher","unstructured":"Harrison C (2020) \u201cCoronavirus puts drug repurposing on the fast track.,\u201d Nature biotechnology, vol. 38, no. 4. United States, pp. 379\u2013381, https:\/\/doi.org\/10.1038\/d41587-020-00003-1.","DOI":"10.1038\/d41587-020-00003-1"},{"issue":"11","key":"5457_CR49","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.3390\/ijms21113793","volume":"21","author":"A Gimeno","year":"2020","unstructured":"Gimeno A et al (2020) Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition. Int J Mol Sci 21(11):3793. https:\/\/doi.org\/10.3390\/ijms21113793","journal-title":"Int J Mol Sci"},{"issue":"9","key":"5457_CR50","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/v12091022","volume":"12","author":"SLP Scroggs","year":"2020","unstructured":"Scroggs SLP et al (2020) Old drugs with new tricks: efficacy of fluoroquinolones to suppress replication of flaviviruses. Viruses 12(9):1022. https:\/\/doi.org\/10.3390\/v12091022","journal-title":"Viruses"},{"issue":"9","key":"5457_CR51","doi-asserted-by":"publisher","first-page":"e0238907","DOI":"10.1371\/journal.pone.0238907","volume":"15","author":"Y Taguchi","year":"2020","unstructured":"Taguchi Y, Turki T (2020) A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction. PLoS One 15(9):e0238907. https:\/\/doi.org\/10.1371\/journal.pone.0238907","journal-title":"PLoS One"},{"issue":"12","key":"5457_CR52","doi-asserted-by":"publisher","first-page":"8338","DOI":"10.1021\/acs.est.1c07655","volume":"56","author":"Y Hu","year":"2022","unstructured":"Hu Y, Wei X, Zhu Q, Li L, Liao C, Jiang G (2022) COVID-19 pandemic impacts on humans taking antibiotics in China. Environ Sci Technol 56(12):8338\u20138349. https:\/\/doi.org\/10.1021\/acs.est.1c07655","journal-title":"Environ Sci Technol"},{"issue":"04","key":"5457_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3855\/jidc.14404","volume":"15","author":"L Mustafa","year":"2021","unstructured":"Mustafa L, Tolaj I, Baftiu N, Fejza H (2021) Use of antibiotics in COVID-19 ICU patients. J Infect Dev Ctries 15(04):501\u2013505. https:\/\/doi.org\/10.3855\/jidc.14404","journal-title":"J Infect Dev Ctries"},{"issue":"1","key":"5457_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12941-021-00444-9","volume":"20","author":"A Yacouba","year":"2021","unstructured":"Yacouba A, Olowo-okere A, Yunusa I (2021) Repurposing of antibiotics for clinical management of COVID-19: a narrative review. Ann Clin Microbiol Antimicrob 20(1):37. https:\/\/doi.org\/10.1186\/s12941-021-00444-9","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"11","key":"5457_CR55","doi-asserted-by":"publisher","first-page":"ofaa517","DOI":"10.1093\/ofid\/ofaa517","volume":"7","author":"EJC Goldstein","year":"2020","unstructured":"Goldstein EJC, Tillotson G, Redell M (2020) Antimicrobial management of respiratory infections in severe acute respiratory syndrome coronavirus 2 patients: clinical and antimicrobial stewardship programs conundrums. Open Forum Infect Dis 7(11):ofaa517. https:\/\/doi.org\/10.1093\/ofid\/ofaa517","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"5457_CR56","doi-asserted-by":"publisher","first-page":"128","DOI":"10.51847\/fe1ioiptwd","volume":"11","author":"ZA Damanhouri","year":"2021","unstructured":"Damanhouri ZA, Alkreathy HM, Ali AS, Karim S (2021) The potential role of fluoroquinolones in the management of COVID-19 a rapid review. J Adv Pharm Educ Res 11(1):128\u2013134. https:\/\/doi.org\/10.51847\/fe1ioiptwd","journal-title":"J Adv Pharm Educ Res"},{"issue":"1","key":"5457_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/v13010008","volume":"13","author":"SLP Scroggs","year":"2020","unstructured":"Scroggs SLP et al (2020) Fluoroquinolone antibiotics exhibit low antiviral activity against SARS-CoV-2 and MERS-CoV. Viruses 13(1):8. https:\/\/doi.org\/10.3390\/v13010008","journal-title":"Viruses"},{"issue":"7","key":"5457_CR58","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.arcmed.2020.06.004","volume":"51","author":"I Karampela","year":"2020","unstructured":"Karampela I, Dalamaga M (2020) Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res 51(7):741\u2013742. https:\/\/doi.org\/10.1016\/j.arcmed.2020.06.004","journal-title":"Arch Med Res"},{"issue":"6","key":"5457_CR59","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s43440-020-00169-0","volume":"72","author":"K Marciniec","year":"2020","unstructured":"Marciniec K, Beberok A, P\u0119cak P, Boryczka S, Wrze\u015bniok D (2020) Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharmacol Reports 72(6):1553\u20131561. https:\/\/doi.org\/10.1007\/s43440-020-00169-0","journal-title":"Pharmacol Reports"},{"issue":"suppl_2","key":"5457_CR60","doi-asserted-by":"publisher","first-page":"W368","DOI":"10.1093\/nar\/gki464","volume":"33","author":"JC Gordon","year":"2005","unstructured":"Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A (2005) H++: a server for estimating p Ka s and adding missing hydrogens to macromolecules. Nucleic Acids Res. 33(suppl_2):W368\u2013W371. https:\/\/doi.org\/10.1093\/nar\/gki464","journal-title":"Nucleic Acids Res."},{"key":"5457_CR61","doi-asserted-by":"publisher","unstructured":"Anandakrishnan R, Aguilar B, Onufriev AV (2012) \u201cH++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res 40, no. Web Server issue, pp. W537\u201341. https:\/\/doi.org\/10.1093\/nar\/gks375","DOI":"10.1093\/nar\/gks375"},{"issue":"2","key":"5457_CR62","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"key":"5457_CR63","doi-asserted-by":"publisher","unstructured":"Morris GM, Huey R, Olson AJ (2008) Using AutoDock for ligand\u2010receptor docking.\u00a0Curr Protoc Bioinforma 24(1). https:\/\/doi.org\/10.1002\/0471250953.bi0814s24","DOI":"10.1002\/0471250953.bi0814s24"},{"key":"5457_CR64","first-page":"779","volume":"20","author":"DS Biovia","year":"2016","unstructured":"Biovia DS (2016) BIOVIA discovery studio visualizer. Softw version 20:779","journal-title":"Softw version"},{"issue":"11","key":"5457_CR65","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 29(11):1859\u20131865. https:\/\/doi.org\/10.1002\/jcc.20945","journal-title":"J Comput Chem"},{"issue":"10","key":"5457_CR66","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks BR et al (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30(10):1545\u20131614. https:\/\/doi.org\/10.1002\/jcc.21287","journal-title":"J Comput Chem"},{"issue":"1","key":"5457_CR67","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","volume":"12","author":"J Lee","year":"2016","unstructured":"Lee J et al (2016) Charmm-Gui Input Generator For Namd, Gromacs, Amber, Openmm, And Charmm\/Openmm Simulations Using The Charmm36 Additive Force Field. J Chem Theory Comput 12(1):405\u2013413. https:\/\/doi.org\/10.1021\/acs.jctc.5b00935","journal-title":"J Chem Theory Comput"},{"issue":"9","key":"5457_CR68","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1021\/ct300400x","volume":"8","author":"RB Best","year":"2012","unstructured":"Best RB et al (2012) Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone \u03d5, \u03c8 and side-chain \u03c71 and \u03c72 dihedral angles. J Chem Theory Comput 8(9):3257\u20133273. https:\/\/doi.org\/10.1021\/ct300400x","journal-title":"J Chem Theory Comput"},{"issue":"16","key":"5457_CR69","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","volume":"26","author":"JC Phillips","year":"2005","unstructured":"Phillips JC et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26(16):1781\u20131802. https:\/\/doi.org\/10.1002\/jcc.20289","journal-title":"J Comput Chem"},{"issue":"2","key":"5457_CR70","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","volume":"79","author":"WL Jorgensen","year":"1983","unstructured":"Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79(2):926\u2013935. https:\/\/doi.org\/10.1063\/1.445869","journal-title":"J Chem Phys"},{"issue":"31","key":"5457_CR71","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/jcc.23067","volume":"33","author":"W Yu","year":"2012","unstructured":"Yu W, He X, Vanommeslaeghe K, MacKerell AD Jr (2012) Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations. J Comput Chem 33(31):2451\u20132468. https:\/\/doi.org\/10.1002\/jcc.23067","journal-title":"J Comput Chem"},{"issue":"5","key":"5457_CR72","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/00268978300102851","volume":"50","author":"S Nos\u00e9","year":"1983","unstructured":"Nos\u00e9 S, Klein ML (1983) Constant pressure molecular dynamics for molecular systems. Mol Phys 50(5):1055\u20131076. https:\/\/doi.org\/10.1080\/00268978300102851","journal-title":"Mol Phys"},{"issue":"5","key":"5457_CR73","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1103\/physreva.33.3628","volume":"33","author":"GS Grest","year":"1986","unstructured":"Grest GS, Kremer K (1986) Molecular dynamics simulation for polymers in the presence of a heat bath. Phys Rev A, Gen Phys 33(5):3628\u20133631. https:\/\/doi.org\/10.1103\/physreva.33.3628","journal-title":"Phys Rev A, Gen Phys"},{"issue":"12","key":"5457_CR74","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden T, York D, Pedersen L (1993) Particle mesh Ewald: an N\u22c5log(N) method for Ewald sums in large systems. J Chem Phys 98(12):10089\u201310092. https:\/\/doi.org\/10.1063\/1.464397","journal-title":"J Chem Phys"},{"issue":"19","key":"5457_CR75","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A smooth particle mesh Ewald method. J Chem Phys 103(19):8577\u20138593. https:\/\/doi.org\/10.1063\/1.470117","journal-title":"J Chem Phys"},{"issue":"4","key":"5457_CR76","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jmv.27526","volume":"94","author":"S Kumar","year":"2022","unstructured":"Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G (2022) Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol 94(4):1641\u20131649. https:\/\/doi.org\/10.1002\/jmv.27526","journal-title":"J Med Virol"},{"issue":"2","key":"5457_CR77","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1359-0278(98)00019-4","volume":"3","author":"BA Reva","year":"1998","unstructured":"Reva BA, Finkelstein AV, Skolnick J (1998) What is the probability of a chance prediction of a protein structure with an rmsd of 6 \u00e5? Fold Des 3(2):141\u2013147. https:\/\/doi.org\/10.1016\/S1359-0278(98)00019-4","journal-title":"Fold Des"},{"issue":"4","key":"5457_CR78","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1134\/S0026893308040195","volume":"42","author":"MY Lobanov","year":"2008","unstructured":"Lobanov MY, Bogatyreva NS, Galzitskaya OV (2008) Radius of gyration as an indicator of protein structure compactness. Mol Biol 42(4):623\u2013628. https:\/\/doi.org\/10.1134\/S0026893308040195","journal-title":"Mol Biol"},{"issue":"6","key":"5457_CR79","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1134\/S0026893308060150","volume":"42","author":"NS Bogatyreva","year":"2008","unstructured":"Bogatyreva NS, Ivankov DN (2008) The relationship between the solvent-accessible surface area of a protein and the number of native contacts in its structure. Mol Biol 42(6):932. https:\/\/doi.org\/10.1134\/S0026893308060150","journal-title":"Mol Biol"},{"issue":"5","key":"5457_CR80","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1021\/bm8015169","volume":"10","author":"AK Shaytan","year":"2009","unstructured":"Shaytan AK, Shaitan KV, Khokhlov AR (2009) Solvent accessible surface area of amino acid residues in globular proteins: correlation of apparent transfer free energies with experimental hydrophobicity scales. Biomacromol 10(5):1224\u20131237. https:\/\/doi.org\/10.1021\/bm8015169","journal-title":"Biomacromol"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-023-05457-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-023-05457-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-023-05457-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T03:10:31Z","timestamp":1678072231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-023-05457-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5457"],"URL":"https:\/\/doi.org\/10.1007\/s00894-023-05457-z","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript does not include any experiments on humans or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The corresponding author consents on behalf of all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The corresponding author consents on behalf of all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}